本文選題：宮頸癌 + 調(diào)強(qiáng)放療��； 參考：《安徽醫(yī)科大學(xué)學(xué)報(bào)》2017年06期

【摘要】：目的評(píng)價(jià)調(diào)強(qiáng)放療聯(lián)合重組人p53腺病毒注射液治療中晚期宮頸癌的近期臨床療效。方法 46例中晚期宮頸癌患者隨機(jī)分為治療組(調(diào)強(qiáng)放療聯(lián)合p53基因治療)21例和對(duì)照組(單純調(diào)強(qiáng)放療)25例。治療組給予重組人p53腺病毒注射液瘤內(nèi)注射每周1次,兩組患者放療劑量和放療方法相同,治療結(jié)束2個(gè)月后,復(fù)查評(píng)估治療療效;并于放療前后刷取宮頸細(xì)胞,行DNA倍體定量分析,比較兩組患者宮頸細(xì)胞DNA指數(shù)≥2.5的細(xì)胞個(gè)數(shù)。結(jié)果治療組完全緩解(CR)13例(61.9%),部分緩解(PR)6例(28.6%),有效率90.5%;對(duì)照組CR 7例(28%),PR 9例(36%),有效率64.0%;治療組有效率明顯高于對(duì)照組(P0.05)。DNA倍體定量分析放療后治療組與對(duì)照組差異有統(tǒng)計(jì)學(xué)意義(χ~2=4.544,P=0.033)。結(jié)論影像學(xué)及DNA倍體定量分析結(jié)論一致,提示重組人p53腺病毒聯(lián)合調(diào)強(qiáng)放療治療中晚期宮頸癌近期療效優(yōu)于單獨(dú)放療組。
[Abstract]:Objective to evaluate the short-term efficacy of IMRT combined with recombinant human p53 adenovirus injection in the treatment of advanced cervical cancer. Methods Forty-six patients with advanced cervical cancer were randomly divided into two groups: treatment group (n = 21) and control group (n = 25). The treatment group was treated with recombinant human p53 adenovirus injection once a week. The dose of radiotherapy was the same as that of radiotherapy in both groups. After 2 months of treatment, the therapeutic effect was evaluated, and cervical cells were brushed before and after radiotherapy. Quantitative analysis of DNA ploidy was performed to compare the number of cervical cell DNA index 鈮，

本文編號(hào)：1821059